Our findings show two documented and relevant possibilities of estimating with a high precision the risk exposure of the patient towards developing MetS: measuring HDL, insulin or ALR in the laboratory or determining trunk fat-free mass, WHtR or trunk fat mass. This evidence concerns the gene INS and metabolic syndrome.